Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 3/20 | 0.32 |
| ▸ | MMP9 | P14780 | 3/20 | 0.32 |
| ▸ | MMP13 | P45452 | 3/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5059324 | 0.91 | SMAD3 (0.35) | TP53MAPT | |
| SCHEMBL610098 | 0.61 | CYP3A4 (0.55) | NOTUMMAPT | |
| SCHEMBL20562234 | 0.60 | CYP3A4 (0.46) | NOTUMMAPT | |
| SCHEMBL3310733 | 0.59 | KDR (0.43) | NOTUMMAPT | |
| SCHEMBL3599330 | 0.58 | KDM4E (0.58) | TP53MAPT | |
| SCHEMBL1636595 | 0.57 | KDM4E (0.43) | MMP1MMP9MMP13ADAM17NOTUM | |
| SCHEMBL1229320 | 0.57 | KDM4E (0.43) | MMP1MMP9MMP13ADAM17NOTUM | |
| SCHEMBL20561922 | 0.57 | CYP3A4 (0.42) | NOTUMMAPT | |
| SCHEMBL184614 | 0.57 | NOTUM (0.67) | NOTUMMAPT | |
| Methyl 3,5-Dibromobenzoate SCHEMBL2408987 | 0.57 | NOTUM (0.67) | NOTUMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498341-B2 | antidiabetic agents; type 2 diabetes | SANOFI AVENTIS DEUTSCHLAND GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7402674-B2 | 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH, (DE) | 2008-07-22 | — | — | US | disclosed |
| US-20050182085-A1 | 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-08-18 | — | — | US | disclosed |
| US-20050182086-A1 | antidiabetic agents; type 2 diabetes | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182086-A1 | antidiabetic agents; type 2 diabetes | SLC5A2, SLC5A1, SLC2A2 | MMP1 3807/4885MMP9 4060/4885MMP13 3611/4885 |
| US-20050182085-A1 | 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments | SLC5A2, CYP2A7, GLS | MMP1 3762/4885MMP9 3728/4885MMP13 3221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.